Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation.

ABSTRACT: Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer's disease (AD). Emerging generative artificial intelligence (GAI) technologies like ChatGPT offer the promise of expediting the review and summary of scientific knowledge. To examine the feasibility of using GAI for identifying drug repurposing candidates, we iteratively tasked ChatGPT with proposing the twenty most promising drugs for repurposing in AD, and tested the top ten for risk of incident AD in exposed and unexposed individuals over age 65 in two large clinical datasets: (1) Vanderbilt University Medical Center and (2) the All of Us Research Program. Among the can

SUBMITTER: Yan C 

PROVIDER: S-EPMC10897392 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature